Open AccessGlucagon-Like Peptide-1 Receptor Agonist Use and Renal Impairment: A Retrospective Analysis of an Electronic Health Records Database in the U.S. Population
Author(s) -
Kristina S. Boye,
Fady T. Botros,
Axel Haupt,
Brad Woodward,
Maureen J. Lage
Publication year - 2018
Publication title -
diabetes therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.907
H-Index - 33
ISSN - 1869-6961
DOI - 10.1007/s13300-018-0377-5
Subject(s) - medicine , health records , diabetes mellitus , agonist , glucagon like peptide 1 receptor , database , population , population health , endocrinology , receptor , health care , environmental health , computer science , economics , economic growth
The study characterizes the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in patients with type 2 diabetes (T2D) with and without renal impairment and examines the effects of such use on the clinical outcomes of estimated glomerular filtration rate (eGFR) and glycated hemoglobin (A1c).